Metabolic Performance

The September 2026 Nature Metabolism study (Petersen et al., PMID 42744908) shows that combining retatrutide, a GLP-1R/GIPR/GCGR tri-agonist, with cagrilintide, a long-acting amylin/calcitonin receptor agonist, produces greater fat loss and improved cholesterol, triglycerides, and insulin versus either compound alone in obese male rats. The mechanistic rationale is receptor non-overlap: incretin and amylin pathways engage distinct neural and peripheral circuits.

In the Phase 2 COURAGE trial, semaglutide 2.4 mg alone lost approximately 7 kg fat and 3 kg lean mass over 26 weeks, with roughly 35% of total weight loss from lean tissue. Adding trevogrumab (anti-GDF8/myostatin) cut lean-mass loss by approximately half while amplifying fat-mass reduction, without attenuating total weight loss or metabolic benefits.

At retatrutide's weight loss of 28 percent (TRIUMPH-1, 80 weeks), calorie restriction alone loses roughly 35 percent of total weight as lean tissue, approximately 9–11 kg on a 90 kg baseline. Combining resistance training with protein at or above 1·6 g/kg/day can reduce that lean fraction to 10–15 percent, protecting an estimated 6–9 kg. No retatrutide-specific RCT confirms this arithmetic.

TRIUMPH-2's 80-week Phase 3 data show retatrutide at 12 mg produced 20.8% mean body-weight loss in adults with type 2 diabetes — 7.5 percentage points below non-diabetic TRIUMPH-1. The 2025 Coskun DXA sub-study found lean mass comprised approximately 35% of weight lost in the T2D population, driven by compounded anabolic resistance and a pre-existing sarcopenic phenotype.

Resistance training materially preserves lean mass during GLP-1 treatment. The Karakasis 2025 meta-analysis found GLP-1 monotherapy loses approximately 25% of total weight as lean tissue; exercise-combined arms cut that fraction to roughly 10–15%. On a 15 kg semaglutide weight-loss course, structured training can prevent 2–4 kg of lean tissue loss, a 60–70% reduction in lean mass attrition.

GLP-1–based therapies produce measurable lean-mass loss in every controlled trial: 20–39% of total weight lost is lean tissue rather than fat. The 2026 Laverde meta-analysis reframes this as a proportional lean-to-fat ratio improvement, but absolute lean-mass deficits of 3–8 kg remain documented. Whether that penalty matters depends on baseline muscle reserve and co-management of resistance training and protein intake.

MK-677 (ibutamoren) produces a statistically significant but modest lean-mass gain of approximately 1.6 kg above placebo over 12 months in the only controlled human trial. It simultaneously raises fasting glucose, reduces insulin sensitivity, and generated a congestive heart failure signal that terminated a separate elderly-population trial. The lean-mass benefit is real but narrow, and the cardiometabolic cost is not negligible.

Retatrutide's glucagon receptor (GCGR) component creates a dual-edged lean-mass signal: it drives hepatic amino acid catabolism via urea-cycle upregulation — a direct lean-mass liability — while simultaneously increasing energy expenditure through fat oxidation, reducing substrate pressure on muscle protein. Resistance training resolves this tension by redirecting circulating amino acids toward myofibrillar synthesis rather than hepatic gluconeogenesis.

Mostly animal data, with one narrow human exception. A 2026 UCLA Health review of 565 studies across six unapproved peptides concluded that human evidence is sparse and marketing claims substantially outpace the clinical record. MK-677 has the strongest human dataset, but its one meaningful RCT enrolled elderly adults rather than athletes, and total fat mass rose alongside lean-mass gains.

A 2025 meta-analysis by Hays et al found that TRE combined with exercise produced a significant fat-mass reduction and improved HOMA-IR versus exercise-matched controls, while fat-free mass remained statistically unchanged. The benefit is real but modest in absolute terms, and protein intake is the primary moderating variable.

Acute endurance exercise reliably elevates circulating humanin and MOTS-c within minutes of exertion; resistance exercise does not produce the same acute plasma response. Across pooled human studies, exercise-driven MOTS-c rises co-occur with AMPK activation, improved GLUT4 translocation, and reduced HOMA-IR, while humanin increases correlate with attenuated oxidative stress markers — providing a mechanistic bridge between training load and insulin-sensitivity gains.

No controlled trial has directly tested retatrutide combined with resistance training and high protein intake. Mechanistic evidence indicates that mechanical loading and leucine-triggered mTORC1 activation operate through pathways additive to retatrutide's triple-receptor pharmacology. The 2025 Coskun body-composition sub-study reported 35.4% of weight lost as lean tissue without exercise or protein controls.